natgillin/translations-raw huggingface dataset:
Thrombotic events have been reported in neonatal and infant subjects undergoing cardiac bypass procedures while receiving off-label high doses of another C1 inhibitor product (up to 500 Units/kg) to prevent capillary leak syndrome.
Trombotički događaji zabilježeni su u novorođenčadi i dojenčadi podvrgnute postupcima ugradnje srčane premosnice dok su primala visoke doze drugog inhibitora C1 izvan odobrene indikacije (do 500 jedinica/kg) zbog sprječavanja sindroma povećane propusnosti kapilara.
Thrombotic events have been reported in neonatal and infant subjects undergoing cardiac bypass procedures while receiving off-label high doses of another C1 inhibitor product (up to 500 Units/kg) to prevent capillary leak syndrome.
Trombotički događaji zabilježeni su u novorođenčadi i dojenčadi u kojih se radio postupak ugradnje srčane premosnice dok su primali visoke doze drugog inhibitora C1 izvan odobrene indikacije (do 500 jedinica/kg) zbog sprječavanja sindroma povećane propusnosti kapilara.
Thrombotic events were reported in 5 patients, none of which were on antithrombotic therapy at the time of the event, and in each of these cases, the thrombotic event could be attributed to the underlying medical condition of the patient.
Trombotski događaji prijavljeni su u 5 bolesnika od kojih nijedan nije bio na antitrombotskoj terapiji u vrijeme događaja, a u svakom se od ovih slučajeva trombotski događaj mogao pripisati priležećem medicinskom stanju bolesnika.
Thrombotic microangiopathy
Trombotička mikroangiopatija
Thrombotic microangiopathy (1)
trombotička mikroangiopatija (1)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)
trombotička mikroangiopatija (uključujući trombocitopeničnu purpuru i hemolitički uremični sindrom)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome) †
trombotička mikroangiopatija (uključujući trombotičku trombocitopeničnu purpuru i hemolitički uremični sindrom)
Thrombotic microangiopathy (TMA) has been reported in clinical trials of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see section 4.8).
Slučajevi trombotičke mikroangiopatije (TMA) zabilježeni su u kliničkim ispitivanjima pazopaniba kao monoterapije, u kombinaciji s bevacizumabom i u kombinaciji s topotekanom (vidjeti dio 4.8).
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome3
trombotička mikroangiopatija, uključujući trombotičku trombocitopeničk u purpuru/ hemolitički uremički sindrom3
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome3
trombotička mikroangiopatija, uključujući trombotičku trombocitopeničku purpuru/ hemolitički uremički sindrom3
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome#
Trombotička mikroangiopatija uključujući trombotičku trombocitopeničku purpuru/hemolitički uremički sindrom#
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
trombootiča mikroangiopatija uključujući trombotičku trombocitopeničnu purpuru/hemolitički uremički sindrom
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
trombotička mikroangiopatija uključujući trombotičku trombocitopeničku purpuru/hemolitički uremički sindrom
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
trombotička mikroangiopatija uključujući trombotičku trombocitopeničnu purpuru/hemolitički uremički sindrom
thrombotic microangiopathya,b
perforacija nosnog septumaa
Thrombotic microangiopathyh,*
trombotička mikroangiopatijah,
thrombotic thrombocyto penic purpura, hypopro- thrombin- aemia
trombotska trombocitope nična purpura, hipoprotromb inemija
Thrombotic Thrombocytopaenic Purpura (TTP)
Trombotična trombocitopenična purpura (TTP)
Thrombotic thrombocytopaenic purpura (TTP) -see section 4.4
trombotična trombocitopenična purpura (TTP) - vidjeti dio 4.4
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), aplastična anemija, panciopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4.), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, aquired haemophilia A, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4.), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), zatajenje koštane srži*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija, hemolitička anemija u bolesnika s nedostatkom glukoza- 6-fosfat dehidrogenaze (G6PD)* (vidjeti dio 4.4)
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4.), zatajenje koštane srži*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija, hemolitička anemija u bolesnika s nedostatkom glukoza- 6-fosfat dehidrogenaze (G6PD)* (vidjeti dio 4.4)
thrombotic thrombocytopenic purpura, hypoprothrombinaemia
trombotička trombocitopenična purpura, hipoprotrombinemija
Thrombotic/Thromboembolic events (TEEs)
Trombotički/tromboembolijski događaji (TED)
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
Kod bolesnika koji primaju eritropoetski pripravak prijavljeni su trombotički/vaskularni događaji poput ishemije miokarda, infarkta miokarda, cerebrovaskularnog događaja (krvarenje u mozak ili cerebralni infarkt), prolazne ishemije, duboke venske tromboze, arterijske tromboze, plućne embolije, aneurizme, retinalne tromboze i stvaranje ugruška u sustavu za dijalizu.
through 10.7 years in girls (n=369) and 10.6 years in boys (n=326), 9-15 years of age at time of vaccination (median follow-up of 10.0 years and 9.9 years, respectively);
tijekom 10,7 godina u djevojčica (n=369) i 10,6 godina u dječaka (n=326), koji su u vrijeme cijepljenja bili u dobi od 9 do 15 godina (medijan praćenja 10,0 godina u djevojčica odnosno 9,9 godina u dječaka);
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance
Kroz 360 tjedana liječenja genotipska analiza virusnih izolata, koja je uspješno provedena u 19 od 28 bolesnika kod kojih je potvrđen HIV RNA iznad 400 kopija/ml, je otkrila nepostojanje primarnih ili aktivnih mjesta mutacija u proteazi (amino kiseline na pozicijama 8, 30, 32, 46, 47, 48, 50, 82, 84 i 90) ili fenotipsku rezistenciju inhibitora proteaze.
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance.
Kroz 360 tjedana liječenja genotipska analiza virusnih izolata, koja je uspješno provedena u 19 od 28 bolesnika kod kojih je potvrđen HIV RNA iznad 400 kopija/ml je otkrila nepostojanje primarnih ili aktivnih mjesta mutacija u proteazi (amino kiseline na pozicijama 8, 30, 32, 46, 47, 48, 50, 82, 84 i 90) ili fenotipsku rezistenciju inhibitora proteaze.
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance.
Kroz 360 tjedana liječenja, genotipska analiza virusnih izolata, koja je uspješno provedena u 19 od 28 bolesnika kod kojih je potvrđen HIV RNA iznad 400 kopija/ml je otkrila nepostojanje primarnih ili aktivnih mjesta mutacija u proteazi (amino kiseline na pozicijama 8, 30, 32, 46, 47, 48, 50, 82, 84 i 90) ili fenotipsku rezistenciju inhibitora proteaze.
Through 48 weeks of treatment, the proportion of patients in the tipranavir with ritonavir arm compared to the comparator PI/ritonavir arm with HIV-1 RNA < 400 copies/ml was 30% and 14% respectively, and with HIV-1 RNA < 50 copies/ml was 23% and 10% respectively.
Tijekom 48 tjedana liječenja udio bolesnika s HIV-1 RNA <400 kopija/ml u skupini koja je dobivala tipranavir s ritonavirom iznosio je 30%, a za kontrolni IP/ritonavir skupinu 14% dok je udio bolesnika s HIV-1 RNA <50 kopija/ml iznosio 23% za ispitivanu i 10% za kontrolnu skupinu.
Through 48 weeks of treatment, the proportion of patients in the tipranavir with ritonavir arm compared to the comparator PI/ritonavir arm with HIV-1 RNA < 400 copies/ml was 30% and 14% respectively, and with HIV-1 RNA < 50 copies/ml was 23% and 10% respectively.
Tijekom 48 tjedana liječenja udio bolesnika s HIV-1 RNA <400 kopija/ml u skupini koja je dobivala tipranavir s ritonavirom iznosio je 30%, a za kontrolnu IP/ritonavir skupinu 14% dok je udio bolesnika s HIV-1 RNA <50 kopija/ml iznosio 23% za ispitivanu i 10% za kontrolnu skupinu.
through 9.6 years in men (n=918), 16-26 years of age at time of vaccination (median follow- up of 8.5 years); and through 8.4 years in women (n=684), 24-45 years of age at time of vaccination (median follow-up of 7.2 years).
tijekom 9,6 godina u muškaraca (n=918), koji su u vrijeme cijepljenja bili u dobi od 16 do 26 godina (medijan praćenja 8,5 godina) i tijekom 8,4 godina u žena (n=684) koje su u vrijeme cijepljenja bile u dobi od 24 do 45 godina (medijan praćenja 7,2 godina).
Through 96 weeks in SPRING-2 and FLAMINGO and 144 weeks in SINGLE, no cases of treatment emergent primary resistance to the integrase- or NRTI-class were seen in the dolutegravir-containing arms.
Tijekom 96 tjedana u ispitivanjima SPRING-2 i ispitivanju FLAMINGO te 144 tjedana u ispitivanju SNGLE, u skupinama koje su primale dolutegravir nisu primijećeni slučajevi primarne rezistencije uzrokovane liječenjem na razred inhibitora integraze niti NRTI-ja.
through a plastic tube placed in your vein (intravenous infusion) usually over 90 minutes
kroz plastičnu cjevčicu uvedenu u venu (intravenska infuzija) obično tijekom 90 minuta
Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.
Primjena otopine jednom mjesečno kod skotnih životinja ili životinja u laktaciji može kroz smanjenje populacije buha pomoći u prevenciji infestacije buhama u leglu do sedam tjedana starosti.
Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age.
Primjena otopine jednom mjesečno kod skotnih životinja ili životinja u laktaciji može kroz smanjenje populacije buha pomoći u prevenciji infestacije buhama u leglu do sedam tjedana starosti.
Through a series of multiple stepwise regression analyses of baseline and on-treatment genotypes from all clinical studies, 16 amino acids have been associated with reduced tipranavir susceptibility and/or reduced 48-week viral load response: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D and 84V. Clinical isolates that exhibited a  10-fold decrease in tipranavir susceptibility harboured 8 or more tipranavir-associated mutations.
Stupnjevita multivarijatna regresijska analiza združenosti genotipova (određenih na početku liječenja ili tijekom liječenja) i terapijskog odgovora ukazala je da je 16 aminokiselina združeno sa smanjenom osjetljivošću na tipranavir i/ili sa manjem odgovorom u smislu broja virusnih replika nakon 48 tjedana liječenja: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D i 84V. Klinički izolati koji su pokazali  10-struko smanjenje osjetljivosti na tipranavir imali su 8 ili više mutacija povezanih s tipranavirom.
Through approximately 2 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar to the general population.
Tijekom približno 4 godine praćenja incidencija malignih bolesti koje nisu limfomi (osim nemelanomskog raka kože) bila je slična onoj u općoj populaciji.
Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.
Pomoću ovih mehanizama fenofibrat povećava lipolizu i eliminaciju trigliceridima bogatih čestica iz plazme tako da aktivira lipoprotein lipazu a smanjuje stvaranje apoproteina C-III.
Through week 24 0.40d
Do 24. tjedna 0,40d
Through week 24 0.40d 0.0016 NA
Do 24. tjedna 0,40d 0,0016 NA NA
Through week 24 8.1 <0.0001 6.1 (4.7, 11.4) (-1.4, 13.5)
Do 24. tjedna 8,1 < 0,0001 6,1 0,1092 (4,7; 11,4) (-1,4; 13,5)
Through week 24, two patients who switched to Eviplera at baseline (2 of 317 patients, 0.6%) and one patient who maintained their ritonavir-boosted protease inhibitor-based regimen [Stayed on Baseline Regimen (SBR) arm] (1 of 159 patients, 0.6%) developed genotypic and/or phenotypic resistance to study drugs.
Do 24. tjedna, dva pacijenta koji su se prebacili na lijek Eviplera na početku (2 od 317 pacijenata, 0,6%) i jedan pacijent koji se održao na režimu ritonavirom pojačanim inhibitorom proteaze [skupina ostala na početnom režimu liječenja] (1 od 159 pacijenata, 0,6%) razvili su genotipsku i/ili fenotipsku rezistenciju na ispitivane lijekove.
Through Week 240, 3 of the 10 patients experienced virologic breakthrough (≥ 1 log10 increase above nadir).
Do 240. tjedna, u 3 od tih 10 bolesnika nastupio je virološki proboj (≥ 1 log10 povećanje iznad najniže točke).
Through week 48 0.46d
Do 48. tjedna 0,46d
Through week 48 0.46d 0.0012 NA
Do 48. tjedna 0,46d 0,0012 NA NA
through week 54
razdoblju do 54. tjedna
Through week 96, fewer patients in the rilpivirine arm with baseline viral load ≤ 100,000 copies/mL had emerging resistance-associated substitutions and/or phenotypic resistance to rilpivirine (7/288) than patients with baseline viral load > 100,000 copies/mL (30/262).
Do 96. tjedna u skupini koja je primala rilpivirin, manji je broj pacijenata s početnim virusnim opterećenjem ≤ 100 000 kopija/ml razvio supstitucije povezane s rezistencijom i/ili fenotipsku rezistenciju na rilpivirin (7/288) nego pacijenata s početnim virusnim opterećenjem
Throughout your treatment, the doctor will check you for any signs of bleeding. if you have been treated before with medicines similar to Angiox (e.g. lepirudin). before the start of the injection or infusion, the doctor will tell you about the signs of allergic reaction.
Tijekom Vašeg liječenja liječnik će provjeravati svaki znak krvarenja. ako ste prethodno bili liječeni lijekovima sličnim Angioxu (npr. lepirudin). prije nego počnete s injekcijom ili infuzijom, liječnik će Vas obavijestiti o znakovima alergijske reakcije.
Throw away all other used items into your regular household waste.
Sve druge iskorištene predmete bacite u obični kućanski otpad.
Throw away any Bydureon pen that has been frozen.
Svaka brizgalica lijeka Bydureon koja je bila zamrznuta mora se baciti.
Throw away any Byetta pen that has been frozen.
Svaka Byetta brizgalica koja je bila zamrznuta mora se baciti.
Throw away any pen that is kept out of the fridge for more than 30 days.
Bacite brizgalicu koja je bila izvan hladnjaka više od 30 dana.
Throw away any remaining solution.
Bacite svu preostalu otopinu.
Throw away any syringe that is kept out of the fridge for more than 30 days.
Bacite štrcaljka koja je bila izvan hladnjaka više od 30 dana.
Throw away any unused containers one week after opening the foil wrapper-even if the containers are still sealed.
Tjedan dana nakon otvaranja vrećice bacite sve neiskorištene spremnike, bez obzira na to što su zatvoreni.
Throw away any unused product in the vial and the disposable supplies as recommended by your healthcare professional.
Bacite svaki neiskorišteni lijek u bočici i materijal za jednokratnu uporabu prema preporuci Vašeg zdravstvenog djelatnika.
Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.
Igle odložite u spremnik otporan na probijanje ili onako kako su Vam je preporučio zdravstveni radnik.
Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.
Igle odložite u spremnik otporan na probijanje ili onako kako Vam je preporučio zdravstveni radnik.
Throw away pen and cap into a puncture-resistant container immediately after use.
Bacite brizgalicu i zatvarač u neprobojan spremnik odmah nakon uporabe.
Throw away syringe and cap into a puncture-resistant container immediately after use.
Bacite štrcaljku i zatvarač u neprobojan spremnik odmah nakon uporabe.
Throw away the bottle 4 weeks after first opening to prevent infections and use a new bottle.
Da bi se spriječile infekcije bocu bacite 4 tjedna nakon prvog otvaranja i uzmite novu bocu.
Throw away the container and any leftover solution at once.
Odmah bacite spremnik zajedno s preostalom otopinom.
Throw away the needle as you have been instructed by your doctor or nurse
Uklonite iglu na način kako su Vam savjetovali Vaš liječnik ili medicinska sestra.
Throw away the needle(s) into the sharps container.
Bacite iglu/e u spremnik za oštre predmete.
Throw away the needle-cap in the puncture resistant container or sharps container.
Zatvarač igle odložite u neprobojan spremnik ili spremnik za oštre predmete.
Throw away the packaging box, inner needle cap, peel tab, alcohol swab and the instructions for use in the household waste.
Odložite u kućni otpad ambalažu, unutarnji zatvarač igle, zaštitnu foliju, vatu natopljenu alkoholom i upute za uporabu.
Throw away the pen you are using after 28 days, even if it still has insulin left in it.
Bacite brizgalicu koju koristite nakon 28 dana, čak i ako u njoj još uvijek ima inzulina.
Throw away the Pen you are using after 28 days, even if it still has insulin left in it.
Brizgalicu koju koristite bacite nakon 28 dana, čak i ako u njoj još uvijek ima inzulina.
Throw away the Pen you are using after the time specified in the Package Leaflet, even if it still has insulin left in it.
Brizgalicu koju koristite bacite nakon što istekne vremenski rok naveden u Uputi o lijeku, čak i ako u njoj još uvijek ima inzulina.
Throw away the tip cap.
Odbacite kapicu za vrh.
Throw away the unused needle with the outer needle cap still on.
Bacite neiskorištenu iglu dok se vanjski poklopac još uvijek nalazi na igli.
Throw away the used needle in a puncture resistant container, or as told by your pharmacist or local authority.
Upotrijebljene igle odložite u neprobojan spremnik ili ih zbrinite sukladno uputama ljekarnika ili lokalnog nadležnog tijela.
Throw away the used Plegridy pen into a special secure container, such as a sharps bin.
Bacite iskorištenu Plegridy brizgalicu u poseban siguran spremnik kao što je spremnik za oštre predmete.
Throw away the used Plegridy pre-filled syringe into a special secure container, such as a sharps bin.
Bacite iskorištenu Plegridy napunjenu štrcaljku u poseban siguran spremnik kao što je spremnik za oštre predmete.
Throw away the used pre-filled pen in a special disposal container as instructed by your doctor, nurse or pharmacist.
Uporabljenu napunjenu brizgalicu bacite u poseban spremnik za zbrinjavanje otpada, kako Vas je uputio Vaš liječnik, medicinska sestra ili ljekarnik.
Throw away used needles in a puncture-resistant container or as recommended by your healthcare professional.
Upotrijebljene igle odložite u spremnik otporan na probijanje ili onako kako preporučuju vaši zdravstveni radnici.
Throw away used syringes in a puncture-resistant container or sharps container.
Upotrijebljene štrcaljke odložite u neprobojan spremnik ili spremnik za oštre predmete.
Throw away your Lyxumia pen, ask your pharmacist how to throw away medicines you no longer use.
Bacite Lyxumia brizgalicu; pitajte svog ljekarnika kako baciti lijekove koje više ne koristite.
Throw away your used pen as told by your pharmacist or local authority.
Upotrijebljenu brizgalicu zbrinite sukladno uputama ljekarnika ili lokalnog nadležnog tijela.
Throw the cap away; it is not needed again.
Bacite zatvarač; nećete ga više trebati.
Throw the needle cover away; it is not needed again.
Bacite poklopac za iglu; nećete ga više trebati.
Throw the needles away after each use.
Igle bacite nakon svake uporabe.
Throw the pre-filled pen away (see figure 10)
Bacite napunjenu brizgalicu u otpad (vidjeti sliku 10)
Throw the pre-filled syringe away (see figure 10)
Bacite napunjenu štrcaljku u otpad (vidjeti sliku 10)
Throw the syringe cap away; it is not needed again.
Bacite zatvarač štrcaljke; nećete ga više trebati.
Throw this sachet away don’t eat or inhale it.
Bacite tu vrećicu – nemojte je progutati niti udisati.
Throw this sachet away don’t eat or inhale it.
Bacite tu vrećicu– nemojte je progutati niti udisati.
Throw this sachet away – do not eat or inhale it.
Bacite tu vrećicu– nemojte je jesti niti udisati.
Throw this sachet away – don’t eat or inhale it.
Bacite tu vrećicu– nemojte je progutati niti udisati.
Throwing away leftover medicine
Zbrinjavanje preostalog lijeka
Throwing away supplies
Uklanjanje otpadnog materijala
throwing up
povraćanje
Throwing up (vomiting)
Povraćanje
Throwing your pen away
Odlaganje brizgalice
Thrush (a fungal infection) in the mouth.
Kandidijaza (gljivična infekcija) usne šupljine.
Thrush (vaginal yeast infection)
Vaginalne gljivične infekcije (kandidijaza)
thrush or genital yeast infection
kandidijaza ili gljivična infekcija spolnih organa
Thu.
Čet.